Group 1 - The company, Haizheng Shengcai (688203.SH), has announced a share buyback program, having repurchased a total of 2.1855 million shares as of January 31, 2026, which represents 1.078% of its total share capital of 203 million shares [1] - The highest price at which the shares were repurchased was 15.98 RMB per share, while the lowest price was 7.76 RMB per share [1] - The total amount spent on the share buyback was 24.2151 million RMB, excluding transaction fees such as stamp duty and trading commissions [1]

Core Viewpoint - Haizheng Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the company [1] - The transition of construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - Haizheng Biomedical Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in higher depreciation and tax expenses, further squeezing profits for the period [1]

Core Viewpoint - Haizheng Shengcai (688203) expects a significant decline in net profit for the fiscal year 2025, projecting a profit of 7.5 million to 9.5 million yuan, representing a year-on-year decrease of 73.24% to 78.88% [2] Financial Performance - The company faces downward pressure on product sales prices, which has compressed the gross profit margin [2] - A decrease in interest income and foreign exchange gains has led to an increase in financial expenses for the period [2] - The transition of some construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further squeezing profits [2]

Core Viewpoint - The company, Haizheng Shengcai (688203.SH), expects a significant decline in net profit for the year 2025, projecting a decrease of 73.24% to 78.88% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company is projected to be between 7.5 million to 9.5 million yuan, a decrease of 26.0046 million to 28.0046 million yuan year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 5.5 million to 7.5 million yuan, reflecting a year-on-year decrease of 75.98% to 82.39% [1] Operational Insights - The company has seen steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - Despite the growth in sales revenue due to deepening and expanding the domestic market, the company faces downward pressure on product sales prices due to market competition [1] Financial Challenges - There has been a year-on-year decrease in interest income and foreign exchange gains, leading to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - The company, Haizheng Shengcai (688203.SH), is expected to see a significant decline in net profit for the year 2025, with projections indicating a decrease of 73.24% to 78.88% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company is projected to be between 7.5 million to 9.5 million yuan, a decrease of 26.0046 million to 28.0046 million yuan year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 5.5 million to 7.5 million yuan, reflecting a year-on-year decrease of 75.98% to 82.39% [1] Operational Insights - The company has seen steady progress in its production and operations, with an upward trend in the sales volume of its main products [1] - Despite the growth in sales revenue due to deepening and expanding the domestic market, the company faces downward pressure on product sales prices due to market competition [1] Financial Challenges - There has been a year-on-year decrease in interest income and foreign exchange gains, leading to an increase in financial expenses [1] - The transition of construction projects from investment to fixed assets has resulted in increased depreciation and tax expenses, further compressing profits for the period [1]

Core Viewpoint - The company, Haizheng Shengcai, expects a significant decline in net profit for the year 2025, projecting a decrease of 73.24% to 78.88% compared to the previous year [1] Financial Projections - The net profit attributable to the parent company is estimated to be between 7.5 million to 9.5 million yuan, a decrease of 26.0046 million to 28.0046 million yuan year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between 5.5 million to 7.5 million yuan, reflecting a reduction of 23.7289 million to 25.7289 million yuan compared to the same period last year [1]

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 7.5 million to 9.5 million yuan, which represents a year-on-year decrease of 73.24% to 78.88% [1] Group 1 - The company cites market competition as a key factor leading to downward pressure on product sales prices, which in turn compresses gross profit margins [1] - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses for the current period [1] - Ongoing construction projects related to fundraising have been capitalized, resulting in increased depreciation and tax expenses, further impacting current profits [1]

证券代码：688203 证券简称：海正生材 公告编号：2026-02 浙江海正生物材料股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净 利润为 750 万元到 950 万元，与上年同期相比，将减少 2,600.46 万元到 2,800.46 万元，同比减少 73.24%到 78.88%。 （2）归属于母公司所有者的扣除非经常性损益的净利润为 550 万元到 750 万元，与上年同期相比，将减少 2,372.89 万元到 2,572.89 万元，同比减少 75.98% 到 82.39%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 四、风险提示 截至本公告披露日，公司未发现影响本次业绩预告内容准确性的重大不确定 因素。 五、其他说明事项 本公告所载预计财务数 ...

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biomaterials Co., Ltd. is experiencing a decline in both revenue and net profit, alongside notable changes in shareholder structure and financing activities [1][2]. Group 2 - On January 26, Haizheng Biomaterials' stock fell by 1.45%, with a trading volume of 38.68 million yuan. The financing buy-in amount was 4.03 million yuan, while the financing repayment was 4.27 million yuan, resulting in a net financing buy of -0.24 million yuan [1]. - As of January 26, the total margin trading balance for Haizheng Biomaterials was 54.57 million yuan, accounting for 3.24% of its market capitalization, which is above the 70th percentile of the past year [1]. - The company specializes in the research, production, and sales of polylactic acid, with its main revenue sources being pure polylactic acid (78.55%), modified polylactic acid (20.50%), and others (0.96%) [1]. - As of September 30, the number of shareholders decreased by 10.22% to 6,695, while the average circulating shares per person increased by 17.43% to 18,538 shares [2]. - For the period from January to September 2025, Haizheng Biomaterials reported a revenue of 621 million yuan, a year-on-year decrease of 5.74%, and a net profit attributable to shareholders of 4.91 million yuan, down 85.34% year-on-year [2]. - The company has distributed a total of 42.49 million yuan in dividends since its A-share listing [2]. - Notable changes in institutional holdings include new entries from several funds, with the top ten circulating shareholders now including new investors such as招商均衡优选混合A and招商品质发现混合A [2].